• No results found

Measles-Mumps-Rubella and Varicella Vaccine Responses in Extremely Preterm Infants

N/A
N/A
Protected

Academic year: 2020

Share "Measles-Mumps-Rubella and Varicella Vaccine Responses in Extremely Preterm Infants"

Copied!
8
0
0

Loading.... (view fulltext now)

Full text

(1)

ARTICLE

Measles-Mumps-Rubella and Varicella Vaccine

Responses in Extremely Preterm Infants

Carl T. D’Angio, MDa, Paulina A. Boohene, MDa, Anne Mowrer, RNb, Susette Audet, BSc, Marilyn A. Menegus, PhDd, D. Scott Schmid, PhDe, Judy A. Beeler, MDc

Departments ofaPediatrics,bMedicine, anddMicrobiology and Immunology, University of Rochester, Rochester, New York;cCenter for Biologics Evaluation and Research,

US Food and Drug Administration, Bethesda, Maryland;eNational VZV Laboratory, Centers for Disease Control and Prevention, Atlanta, Georgia

The authors have indicated they have no financial relationships relevant to this article to disclose.

ABSTRACT

OBJECTIVE.Extremely preterm infants mount lower antibody responses than term infants to several vaccines. The objective of this study was to measure the immu-nogenicity of measles-mumps-rubella and varicella vaccines in preterm and term children.

METHODS.Immune status before immunization and immune response after immu-nization with measles-mumps-rubella and varicella vaccines at 15 months of age

were compared in 32 infants, 16 of whom were preterm (⬍29 weeks’ gestation)

and 16 of whom were term (ⱖ37 weeks’ gestation) at birth. Blood was drawn

before vaccination and 3 to 6 weeks thereafter. Measles antibody was measured by plaque reduction neutralization assay. Mumps and rubella immunoglobulin G were measured in available sera by enzyme-linked fluorescent immunoassay. Varicella immunoglobulin G was measured in available sera by glycoprotein enzyme-linked immunosorbent assay. Values that were above or below the assay limits were assigned values double or half those limits, respectively. The primary outcome was the geometric mean antibody titer.

RESULTS.Preterm children had lower mumps and rubella geometric mean titers than did term children before vaccine, and nearly all children were seronegative for each of the 4 vaccine antigens before immunization. Measles, mumps, rubella, and varicella geometric mean titers were similar between groups after vaccine. All children were seropositive for measles after vaccine, whereas 13 of 14 preterm and 11 of 13 term children were seropositive for mumps, 13 of 14 preterm and 13 of 13 term children were seropositive for rubella, and 11 of 16 preterm and 9 of 15 term children were seropositive for varicella.

CONCLUSIONS.Preterm children mounted antibody responses that were similar to those of term children after measles-mumps-rubella and varicella vaccines at 15 months of age.

www.pediatrics.org/cgi/doi/10.1542/ peds.2006-2241

doi:10.1542/peds.2006-2241

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funding agencies.

Key Words

vaccines, premature infant, measles-mumps-rubella vaccine, varicella vaccine, very low birth weight infant, immunology, humoral immunity, immunization

Abbreviations

MMR—measles-mumps-rubella GMT— geometric mean titer IgG—immunoglobulin G

ELISA— enzyme-linked immunosorbent assay

RFV—relative fluorescence value OD— optical density

Accepted for publication Oct 18, 2006

Address correspondence to Carl T. D’Angio, MD, Box 651, Neonatology, University of Rochester, 601 Elmwood Ave, Rochester, NY 14642. E-mail: carl_dangio@urmc.rochester. edu

(2)

T

HE AMERICAN ACADEMY of Pediatrics recommends that preterm infants receive most vaccines, includ-ing the measles-mumps-rubella (MMR) and varicella

vaccines, at the same chronologic age as term infants.1

However, extremely preterm infants (born at ⬍28 –30

weeks’ gestation) have lower antibody responses than

term infants to several vaccines, including Haemophilus

influenzae type b,2–6 hepatitis B,7–11 and polio,12,13 when

these vaccines are given at the postnatal ages that are recommended for term infants. The immunogenicity of vaccine series that are begun during the first 6 months in preterm infants may remain diminished after the

admin-istration of toddler14,15and school-age15,16boosters.

Inac-tivated influenza vaccine, which is administered at or after 6 months of age, also seems to be less immunogenic

in preterm than term infants.17 These data raise the

question of whether a relative deficit in humoral immu-nity persists beyond 6 months’ postnatal age in preterm infants.

We evaluated the serologic response of extremely preterm infants to MMR and varicella vaccines that were given at 15 months’ chronologic age. We hypothesized that these children would have lower geometric mean antibody titers (GMT) to varicella, mumps, measles, and rubella after vaccination than infants who were born at term but that a similar number of preterm as term in-fants would become seropositive.

METHODS

Patients

The study was conducted between May 2002 and May 2005. The University of Rochester Institutional Review Board approved the study. Infants were eligible for the

study when they were born at ⬍29 weeks’ or ⱖ37

weeks’ gestation, they were ⬍16 months of age, they

had not yet received MMR or varicella vaccines, and the parents had given permission for and the primary pedi-atrician had agreed to the study. Infants were excluded when they had known immunodeficiency, had contra-indications to vaccination, or required systemic cortico-steroids or oxygen therapy at the time of vaccination. Concurrent administration of other vaccines was per-mitted.

Preterm infants were recruited at the time of a sched-uled visit to the regional perinatal center’s neurodevel-opmental follow-up clinic (at which all infants who were

born at ⬍30 weeks’ gestation were evaluated) at ⬃9 to

12 months of age. Term infants were recruited from either a hospital-based pediatric clinic or a private pedi-atric practice at the time of the 12-month visit. Term infants were matched to preterm infants on race and, whenever possible, on gender.

Study Visits

Written parental permission, demographic and historical information, and a blood specimen were obtained before

immunization. MMR II (Merck Vaccines, Whitehouse Station, NJ) and varicella (Varivax; Merck) vaccines were administered by the primary pediatrician from his or her routine office stock according to the manufactur-ers’ instructions and routine medical care practices. At a visit 3 to 6 weeks after immunization, interim medical history and a blood specimen were obtained.

Serology

Serum was separated and frozen, in 3 aliquots, at⫺80°C

until the time of analysis. Measles antibody was mea-sured by plaque reduction neutralization assay according

to established protocols.18,19Briefly, measles virus (25–30

plaques per well) and serial dilutions of heat-inactivated subject serum were incubated at 36°C, added to Vero cell monolayers in 24-well culture plates in duplicate, and covered with carboxymethylcellulose overlay media. The trays then were incubated for 5 days at 36°C, at which time the monolayers were stained and fixed and the plaques were counted. The end point for the test was calculated using the Ka¨rber formula and reflected the dilution of serum that reduced the number of plaques by 50%. Dilution values were converted to mIU by com-parison with results that were obtained using second International Standard (66/202) tested in parallel; in this assay, a titer of 1:8 was equivalent to 8 mIU/mL. A

neutralizing antibody titer ⱖ120 mIU/mL was

consid-ered evidence of seroresponse.20

Mumps and rubella immunoglobulin G (IgG) titers were measured using a commercially available, auto-mated, enzyme-linked fluorescent immunoassay (VIDAS Vitek ImmunoDiagnostic Assay System; bioMe´rieux, Inc, Hazelwood, MO). Titers were reported as relative

fluores-cence values (RFV). Mumps values⬍0.35 were considered

negative, values 0.35 to 0.49 were considered equivocal

(and treated as negative during analysis), and valuesⱖ0.50

were considered positive. Rubella values⬍0.40 were

con-sidered negative, values 0.40 to 0.49 were concon-sidered equivocal (and treated as negative during analysis), and

valuesⱖ0.50 were considered positive.

Varicella IgG was measured using a glycoprotein en-zyme-linked immunosorbent assay (ELISA) protocol that essentially was the same as that reported by

Was-muth and Miller.21 A twofold end point dilution series

that began with a dilution of 1:20 was performed. Re-sults for each dilution were scored as positive, negative, or equivocal on the basis of empirically determined cut-offs that were based on calculations of cumulative ance of test data from repeated testing of known vari-cella zoster virus–positive and –negative sera by several operators. Titration end points were defined as the high-est dilution to produce a thigh-est result in the equivocal range. All tests were controlled internally using defined positive and negative sera. The reportable range of

re-sults for the glycoprotein ELISA was ⬍0.100 optical

(3)

⫽ equivocal (and treated as negative during analysis),

andⱖ0.250 OD units⫽positive. In the event that the

volume of serum was insufficient to complete all testing, assays were performed in the following priority order: (1) measles, (2) varicella, and (3) mumps and rubella.

Analysis

Antibody titers were normalized by logarithmic transfor-mation and summarized as GMT. For the purposes of the logarithmic transformation, values above or below the limits for each assay were assigned values double or half those limits, respectively. Vaccine titers were compared

using the Mann-WhitneyUtest. Birth weights and ages

were summarized as medians. Categorical variables were

compared using the␹2or Fisher’s exact tests, as

appro-priate. The primary outcome was antibody GMT, and the secondary outcome was the proportion of children who were seropositive for each antibody.

A patient population of 16 patients per group was anticipated to be sufficient to measure a 1.5-fold eleva-tion in term infants’ GMT of antibody over preterm infants’ GMT, assuming an SD of 0.5 times the preterm

infants’ GMT,␣⫽.05, and a power of 0.80, or a twofold

difference assuming an SD the same size as the preterm

infants’ GMT with the same␣and power.

RESULTS

Seventeen preterm infants and 19 term infants were enrolled. One preterm infant and 3 term infants had only 1 successful blood draw performed; their sam-ples were not analyzed. Sixteen preterm infants and 16 term infants had all study procedures completed. Demo-graphic and baseline information is summarized in Table 1.

Four patients in the preterm infant group and 1 pa-tient in the term group had MMR and varicella vaccines given before 15 months of age; all vaccines were given between 14.4 and 16.0 months of age (Table 1). Nine preterm infants received other vaccines (9 heptavalent pneumococcal conjugate vaccine, 1 influenza vaccine) concurrent with MMR and varicella vaccines. This also occurred in 10 term infants (10 heptavalent

pneumo-coccal conjugate vaccine, 1 influenza vaccine). Three infants in each group had minor adverse events in the 6 weeks after immunization, including low-grade fever, upper respiratory signs, and rash. A causal relationship between an adverse reaction and a specific vaccine could not be established. No serious adverse events were noted after immunization.

All patients in both groups were seronegative for measles-neutralizing antibody before vaccine, and all

had measles titers⬎120 mIU/mL after vaccine (Table 2).

Measles titers were similar between groups both before and after vaccine (Fig 1). Preterm infants had lower mumps and rubella titers than did term infants before vaccine; however, the groups had similar titers after vaccine (Fig 1). Similar proportions of infants had posi-tive mumps and rubella antibody seroresponses after vaccine (Table 2). Varicella titers were similar between preterm and term infants both before and after vaccine (Fig 1). All prevaccine varicella titers in both groups fell below the limit of detection. Postvaccine varicella titers were lower than might have been expected, and several infants in both groups had titers below the defined se-roresponse level (Table 2).

DISCUSSION

We have shown that preterm infants who were born at

⬍29 weeks’ gestation mounted antibody responses to

measles, mumps, rubella, and varicella after MMR and varicella vaccination at 15 months of age that were similar to those that were observed in term infants. Prevaccine mumps and rubella titers in preterm infants were lower than those in term infants. This is consistent with lower transplacental antibody transfer in the pre-term infants, because the most likely source of detectable prevaccine antibodies would be maternal. Prevaccine varicella and measles titers fell near or below the assays’ limits of detection in both groups of infants, precluding any evaluation of gestational age effects.

Identification of high-risk groups for poor MMR or varicella vaccine immunogenicity potentially is clinically important. Measles, mumps, and rubella still circulate to a limited degree in the US population, with continued

TABLE 1 Demographic and Baseline Information on Term and Preterm Infants Who Were Immunized at 15 Months of Age With MMR and Varicella Vaccines

Parameter Preterm Infants (n⫽16)

Term Infants (n⫽16)

Gestation, median (range), wk 26.8 (24.0–28.9) 40 (37–40) Birth weight, median (range), g 788 (540–1250) 3488 (2130–4296)

Male,n(%) 8 (50) 7 (44)

White,n(%) 10 (63) 10 (63)

(4)

importation from international sources.22–25Measles and

mumps cause occasional outbreaks,22–24,26and these

ep-idemics tend to cluster in populations with inadequate

immunity.22,23Measles remains a major killer of children

worldwide.27Varicella circulates freely in the US

popu-lation and continues to cause an attenuated chickenpox illness in a significant proportion of vaccine recipients

who are exposed to the virus.28–31Individuals with lower

levels of varicella immunity are more likely to experi-ence a more severe form of varicella disease than those

with higher levels of varicella immunity.28,30,32

Few data existed previously for measles, mumps, ru-bella, or varicella vaccines that were given to infants who were born preterm. Shortly after the introduction of rubella vaccine, a study of 7 term and 5 preterm

(⬍2500 g birth weight) 12- to 25-month-old infants

TABLE 2 Proportions of Term and Preterm Infants Who Were Immunized at 15 Months of Age With MMR and Varicella Vaccines With Vaccine Seroresponses

Antibody (Positive Titer) Sample Preterm Infants,n/N

Term Infants,n/N

P

Measles (ⱖ120 mIU/mL) Prevaccine 0/16 0/16 —

Postvaccine 16/16 16/16 —

Mumps (ⱖ0.5 RFV) Prevaccine 0/14 2/16 0.49

Postvaccine 13/14 11/13 0.60

Rubella (ⱖ0.5 RFV) Prevaccine 0/15 1/16 1.0

Postvaccine 13/14 13/13 1.0

Varicella (ⱖ250 OD Units) Prevaccine 0/16 0/16 —

Postvaccine 11/16 9/15 0.61

FIGURE 1

(5)

showed delayed cellular and humoral rubella vaccine responses in the preterm infants that became equivalent

to those in term infants by 42 days after immunization.33

Many vaccines that first are administered under 6 months of age now have been studied fairly well in

extremely preterm infants.2–13,34Although antibody

lev-els after vaccination in extremely preterm infants tend to be somewhat lower than those that are achieved by term infants, similar proportions of preterm and term infants mount antibody responses above the minimum levels that are considered to be protective against disease.

In contrast to our findings with MMR and varicella vaccines, limited experiences with other vaccines have suggested continued deficits beyond 6 months of age in preterm infants’ vaccine responses. Inactivated influenza vaccine, given at 6 to 18 months of age, elicits lower antibody titers and diminished T-cell proliferative

re-sponses in preterm than in term children.17 We and

others have reported diminished antibody responses

af-ter tetanus, diphtheria, polio, andHaemophilus influenzae

type b booster vaccines in 4- to 7-year-old children who

were born extremely preterm.14–16 The immunologic

mechanisms of the decreased vaccine responses are

un-known but seem to affect both the humoral14–17and the

cellular17arms of the immune system.

The relatively robust vaccine responses in the preterm infants in this study may be explained in part by the specific vaccine antigens studied. Live viral vaccines, such as MMR and varicella, often are highly immuno-genic. Early studies with the varicella vaccine suggested 94% to 100% seroconversion, 93% to 100% cellular immune response, and 90% to 96% efficacy, with

im-munity persisting unabated over 7 to 10 years.35–38

Com-parisons between oral, live, attenuated polio vaccine and injectable, enhanced-potency, inactivated polio vaccine in preterm infants also have suggested that the live

vaccine may be more immunogenic.12,13,15,39

This study has inherent limitations. Relatively few infants were studied. Although the numbers were cal-culated to be sufficient to test the hypothesis of differ-ence between the groups, a lack of detected differdiffer-ence does not necessarily suggest equivalence of the 2 study groups. However, the narrow confidence intervals that were observed in this study (Fig 1) suggest that any true difference between groups is likely to be small and clin-ically insignificant. Vaccines, particularly live vaccines, stimulate both the cellular and the humoral components of the immune system, and cellular responses to the

vaccines studied here have been described.17,33,35,37,40This

study measured only antibody titers. Differences in an-tibody affinity or cellular responses between groups would not be detected. In many cases, however, anti-body levels alone provide a reasonable estimate of

vac-cine immunogenicity.5,41–43In addition, our results

can-not rule out the possibility that some persistent immune system alteration in preterm infants may be overcome

by relatively highly immunogenic, live, attenuated vac-cines such as MMR and varicella vacvac-cines.

CONCLUSION

Administration of MMR and varicella vaccine at the recommended chronologic age results in adequate anti-body response to vaccine antigens, even in infants who are born before 29 weeks’ gestation. These findings sup-port the prevailing recommendations for immunization of the preterm infant at the chronological age appropri-ate for a term infant.

ACKNOWLEDGMENTS

This project was funded in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (Bethesda, MD), under contract N01-A1-25460; by grant 5 M01 RR00044 from the National Center for Research Resources, National Institutes of Health, for the University of Rochester Gen-eral Clinical Research Center; and by the Centers for Disease Control and Prevention.

We thank John Treanor, MD, Diane O’Brien, RN, and Doreen Francis, RN, for support of this project; Jason Roy, PhD, for statistical guidance; and the University of Rochester Neonatal Continuing Care Clinic, the Gol-isano Children’s Hospital at Strong Pediatric Clinic, and Elmwood Pediatrics for help with recruitment. We also thank the infants and their families for participating.

REFERENCES

1. American Academy of Pediatrics. Immunization in special clin-ical circumstances. In: Pickering LK, Baker CJ, Long SS, Mc-Millan JA, eds.Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:67–103

2. Washburn LK, O’Shea TM, Gillis DC, Block SM, Abramson JS. Response to Haemophilus influenzae type b conjugate vaccine in chronically ill premature infants. J Pediatr. 1993;123: 791–794

3. Greenberg DP, Vadheim CM, Partridge S, Chang SJ, Chiu CY, Ward JI. Immunogenicity of Haemophilus influenzae type b tetanus toxoid conjugate vaccine in young infants. The Kaiser-UCLA Vaccine Study Group.J Infect Dis.1994;170:76 – 81 4. Munoz A, Salvador A, Brodsky NL, Arbeter AM, Porat R.

Antibody response of low birth weight infants to Haemophilus influenzae type b polyribosylribitol phosphate-outer mem-brane protein conjugate vaccine.Pediatrics.1995;96:216 –219 5. Heath PT, Booy R, McVernon J, et al. Hib vaccination in infants

born prematurely.Arch Dis Child.2003;88:206 –210

6. Berrington JE, Cant AJ, Matthews JN, O’Keeffe M, Spickett GP, Fenton AC. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/ acellular pertussis/Hib combination vaccine, significant prema-turity, and a fourth dose.Pediatrics.2006;117(4). Available at: www.pediatrics.org/cgi/content/full/117/4/e717

7. Losonsky GA, Wasserman SS, Stephens I, et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization.Pediatrics.1999; 103(2). Available at: www.pediatrics.org/cgi/content/full/103/ 2/e14

(6)

Immu-nogenicity of hepatitis B vaccine in healthy very low birth weight infants.J Pediatr.1997;131:641– 643

9. Linder N, Handsher R, German B, et al. Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simulta-neously shortly after birth. Arch Dis Child Fetal Neonatal Ed. 2000;83:F24 –F27

10. Sood A, Singh D, Mehta S, Midha V, Kumar R. Response to hepatitis B vaccine in preterm babies.Indian J Gastroenterol. 2002;21:52–54

11. Freitas da Motta MS, Mussi-Pinhata MM, Jorge SM, Tachibana Yoshida CF, Sandoval de Souza CB. Immunogenicity of hepa-titis B vaccine in preterm and full term infants vaccinated within the first week of life.Vaccine.2002;20:1557–1562 12. O’Shea TM, Dillard RG, Gillis DC, Abramson JS. Low rate of

response to enhanced inactivated polio vaccine in preterm infants with chronic illness.Clin Res Reg Aff.1993;10:49 –57 13. D’Angio CT, Maniscalco WM, Pichichero ME. Immunologic

response of extremely premature infants to tetanus, Hae-mophilus influenzae, and polio immunizations. Pediatrics. 1995;96:18 –22

14. Khalak R, Pichichero ME, D’Angio CT. Three-year follow-up of vaccine response in extremely preterm infants.Pediatrics.1998; 101:597– 603

15. Conway S, James J, Balfour A, Smithells R. Immunisation of the preterm baby.J Infect.1993;27:143–150

16. Kirmani KI, Lofthus G, Pichichero ME, Voloshen T, D’Angio CT. Seven-year follow-up of vaccine response in extremely premature infants.Pediatrics.2002;109:498 –504

17. Groothuis JR, Levin MJ, Lehr MV, Weston JA, Hayward AR. Immune response to split-product influenza vaccine in preterm and full-term young children.Vaccine.1992;10:221–225 18. Albrecht P, Herrmann K, Burns GR. Role of virus strain in

conventional and enhanced measles plaque neutralization test. J Virol Methods.1981;3:251–260

19. Wong-Chew RM, Islas-Romero R, Garcia-Garcia Mde L, et al. Immunogenicity of aerosol measles vaccine given as the pri-mary measles immunization to nine-month-old Mexican chil-dren.Vaccine.2006;24:683– 690

20. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers.J Infect Dis.1990;162:1036 – 1042

21. Wasmuth EH, Miller WJ. Sensitive enzyme-linked immu-nosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen.J Med Virol.1990;32:189 – 193

22. Centers for Disease Control and Prevention (CDC). Epidemi-ology of measles—United States, 2001–2003.MMWR Morb Mor-tal Wkly Rep.2004;53:713–716

23. Centers for Disease Control and Prevention (CDC). Measles— United States, 2004. MMWR Morb Mortal Wkly Rep.2005;54: 1229 –1231

24. Centers for Disease Control and Prevention (CDC). Update: multistate outbreak of mumps—United States, January 1–May 2, 2006.MMWR Morb Mortal Wkly Rep.2006;55:559 –563 25. Meissner HC, Reef SE, Cochi S. Elimination of rubella from the

United States: a milestone on the road to global elimination. Pediatrics.2006;117:933–935

26. Yeung LF, Lurie P, Dayan G, et al. A limited measles outbreak

in a highly vaccinated US boarding school.Pediatrics.2005;116: 1287–1291

27. Stein CE, Birmingham M, Kurian M, Duclos P, Strebel P. The global burden of measles in the year 2000: a model that uses country-specific indicators. J Infect Dis. 2003;187(suppl 1): S8 –S14

28. Vazquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine.JAMA.2004;291:851– 855

29. Grose C. Varicella vaccination of children in the United States: assessment after the first decade 1995–2005.J Clin Virol.2005; 33:89 –95; discussion 96 – 88

30. Miron D, Lavi I, Kitov R, Hendler A. Vaccine effectiveness and severity of varicella among previously vaccinated children dur-ing outbreaks in day-care centers with low vaccination cover-age.Pediatr Infect Dis J.2005;24:233–236

31. Haddad MB, Hill MB, Pavia AT, et al. Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002–2003.Pediatrics.2005;115:1488 –1493

32. Centers for Disease Control and Prevention (CDC). Varicella-related deaths—United States, January 2003–June 2004. MMWR Morb Mortal Wkly Rep.2005;54:272–274

33. Steele RW, Hensen SA, Vincent MM, Fuccillo DA, Bellanti JA. Development of specific cellular and humoral immune re-sponses in children immunized with live rubella virus vaccine. J Infect Dis.1974;130:449 – 453

34. D’Angio CT, Hall CB. Timing of vaccinations in premature infants.BioDrugs.2000;13:335–346

35. Asano Y, Nagai T, Miyata T, et al. Long-term protective immu-nity of recipients of the OKA strain of live varicella vaccine. Pediatrics.1985;75:667– 671

36. Weibel RE, Kuter BJ, Neff BJ, et al. Live Oka/Merck varicella vaccine in healthy children. Further clinical and laboratory assessment.JAMA.1985;254:2435–2439

37. Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults.Pediatrics.1986;78:748 –756 38. Johnson CE, Shurin PA, Fattlar D, Rome LP, Kumar ML. Live

attenuated varicella vaccine in healthy 12- to 24-month-old children.Pediatrics.1988;81:512–518

39. Adenyi-Jones SC, Faden H, Ferdon MB, Kwong MS, Ogra PL. Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in premature and term infants. J Pediatr.1992;120:686 – 689

40. Esposito S, Faldella G, Giammanco A, et al. Long-term pertus-sis-specific immune responses to a combined diphtheria, teta-nus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term infants.Vaccine.2002;20:2928 –2932

41. Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b.J Infect Dis.1983;147:1100 42. Shinefield HR, Black SB, Staehle BO, et al. Safety, tolerability

and immunogenicity of concomitant injections in separate lo-cations of M-M-R II, Varivax and Tetramune in healthy chil-dren vs. concomitant injections of M-M-R II and Tetramune followed six weeks later by Varivax.Pediatr Infect Dis J.1998; 17:980 –985

(7)

DOI: 10.1542/peds.2006-2241

2007;119;e574

Pediatrics

Menegus, D. Scott Schmid and Judy A. Beeler

Carl T. D'Angio, Paulina A. Boohene, Anne Mowrer, Susette Audet, Marilyn A.

Infants

Measles-Mumps-Rubella and Varicella Vaccine Responses in Extremely Preterm

Services

Updated Information &

http://pediatrics.aappublications.org/content/119/3/e574 including high resolution figures, can be found at:

References

http://pediatrics.aappublications.org/content/119/3/e574#BIBL This article cites 40 articles, 12 of which you can access for free at:

Subspecialty Collections

b

http://www.aappublications.org/cgi/collection/infectious_diseases_su Infectious Disease

following collection(s):

This article, along with others on similar topics, appears in the

Permissions & Licensing

http://www.aappublications.org/site/misc/Permissions.xhtml in its entirety can be found online at:

Information about reproducing this article in parts (figures, tables) or

Reprints

(8)

DOI: 10.1542/peds.2006-2241

2007;119;e574

Pediatrics

Menegus, D. Scott Schmid and Judy A. Beeler

Carl T. D'Angio, Paulina A. Boohene, Anne Mowrer, Susette Audet, Marilyn A.

Infants

Measles-Mumps-Rubella and Varicella Vaccine Responses in Extremely Preterm

http://pediatrics.aappublications.org/content/119/3/e574

located on the World Wide Web at:

The online version of this article, along with updated information and services, is

by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397.

Figure

TABLE 1Demographic and Baseline Information on Term and Preterm Infants Who Were Immunized at15 Months of Age With MMR and Varicella Vaccines
TABLE 2Proportions of Term and Preterm Infants Who Were Immunized at 15 Months of Age WithMMR and Varicella Vaccines With Vaccine Seroresponses

References

Related documents

In this view, we are still able to experience carnivalesque laughter, but in certain contexts, and especially inside pedagogical institutions, this pure form of laughter is

The results show that 61.8% of managers agreed, 27.3% strongly agreed, and 9.1% were neutral about involving others, while 21.3% of subordinates strongly agreed, 34.7% agreed,

In the same direction, the (Bhaduri , 2016) study of the Indian economy concluded that although inflation has a negative impact on economic growth on the short term,

Besides the tensile strength of longitudinal steel bars, the shear capacity provided by the concrete on the top of the diagonal crack, the tensile force of the shear steel at

Disease related factors associated with early rheumatoid arthritis over the first two years are associated with differential predictive risk for incident

This 15-year follow-up study focused on the permanent consequences of RA: radiographic outcome, functional capacity and permanent work disability in 86 patients with early RA (≤

analyzing the potential surrounding environment was carried out in the same way by three teachers in three different schools, however, the results have shown

Our results demonstrated that the combination of FA-CS-mIP-10 and TRP2-specific CD8 + CD28 + T cells not only inhibited the angiogenesis and proliferation of tumor but also